Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-01-14
1993-07-27
Brown, Johnnie R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 276, A61K 3170, C07H 19167
Patent
active
052310868
ABSTRACT:
This invention is concerned with the use of adenosine as an agent for the treatment of human beings. More particularly, this invention is concerned with the administration of adenosine to human patients by continuous intravenous infusion for, inter alia, control of blood pressure, use as a selective vasodilator, decreasing pulmonary vascular resistance, treating acute pulmonary hypertension in conjunction with idiopathic respiratory distress syndrome, in diagnosing pulmonary hypertension in conjunction with cardiac septum defects, in percutaneous transluminal angioplasty (PTCA), in coronary thrombolysis (CTL) and in radionucleide scintography.
REFERENCES:
patent: 4673563 (1987-06-01), Berne et al.
Fukunaga et al.(I), Anesthesia and Analgesia, 61, 273-278 (1982).
Fukunaga et al.(II), Anesthesiology, 57(3), A65 (1982).
Masters et al., Thorac. Cardiovasc. Surgeon, 30, 14-20 (1982).
Kassel et al., J. Neurosurg., 58, 69-76 (1983).
Sollevi et al., Acta Physiol. Scand., 120, 171-176 (1984).
Olsson et al., Circulation Research, 45(4), 468-478 (1979).
Brown Johnnie R.
Crane L. Eric
Item Development Aktiebolag
LandOfFree
Continuous administration adenosine to increase myocardial blood does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Continuous administration adenosine to increase myocardial blood, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Continuous administration adenosine to increase myocardial blood will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2342358